```html

Jean‑Leroy Disease – A Complete Patient‑Friendly Guide

Overview

Jean‑Leroy disease (also called idiopathic progressive osteolysis or “multifocal osteolysis”) is a rare, hereditary bone‑remodeling disorder characterized by the gradual loss (osteolysis) of bone tissue in multiple skeletal sites. The disease typically begins in childhood or early adolescence and can progress to severe deformities, joint instability, and functional impairment.

• Who it affects: Primarily males (≈ 70 % of reported cases) but females are also reported. The condition follows an X‑linked dominant inheritance pattern, meaning a single mutated gene on the X chromosome can cause disease in both sexes, with males often more severely affected.
• Prevalence: Extremely rare; fewer than 200 cases have been documented worldwide to date. The exact incidence is unknown, but estimates range from 1 per 1 million to 1 per 5 million live births.<sup>1</sup>
• Age of onset: Most patients present between ages 5 and 15, although late‑onset cases (up to age 30) have been described.

Symptoms

Symptoms vary according to the bones involved and the disease stage. Early signs are often subtle and can be mistaken for growing‑pain or sports injuries.

Common early symptoms

• Localized bone pain: Dull or aching pain that worsens with activity and improves with rest.
• Swelling or tenderness: Over the affected bone or joint.
• Difficulty walking or running: Especially when the lower limbs are involved.

Progressive signs

• Bone loss visible on X‑ray: Progressive radiolucent areas (holes) in long bones, ribs, or vertebrae.
• Joint instability & subluxation: Frequent “giving way” of joints, particularly the knee, ankle, and shoulder.
• Deformities: Bowing of long bones, limb length discrepancy, or abnormal curvature of the spine (scoliosis, kyphosis).
• Pathological fractures: Fractures that occur with minimal or no trauma.
• Dental abnormalities: Early loss of teeth or abnormal tooth eruption due to jaw bone loss.
• Skin changes: Overlying skin may become thin, translucent, or develop “cobblestone” nodules (rare).

Systemic manifestations (less common)

• Fatigue
• Low‑grade fever
• Growth retardation in severely affected children

Causes and Risk Factors

Jean‑Leroy disease is caused by mutations in the ZNF469 gene, which encodes a transcription factor involved in bone matrix regulation. The mutation leads to uncontrolled osteoclast activity (cells that break down bone) and impaired osteoblast function (cells that form bone).

Genetic inheritance

• X‑linked dominant: A mother carrying the mutation has a 50 % chance of passing it to each child, regardless of sex. Affected males pass the mutation to all daughters but none of their sons.
• De novo mutations: Approximately 30 % of cases arise from new genetic changes with no family history.

Risk factors

• Having a parent or close relative with a confirmed genetic diagnosis.
• Male sex (higher severity due to having only one X chromosome).
• Ethnic clusters: Slightly higher reporting from families of Northern European descent, possibly reflecting reporting bias.

Diagnosis

Because the condition mimics other bone disorders, a systematic diagnostic approach is essential.

Clinical assessment

• Detailed medical and family history (including pedigree analysis).
• Physical examination focusing on joint stability, limb length, and spinal alignment.

Imaging studies

• Plain radiographs (X‑ray): First‑line; shows characteristic osteolytic lesions, cortical thinning, and bone resorption.
• CT scan: Provides 3‑dimensional detail of complex anatomy, especially in the spine or pelvis.
• MRI: Evaluates bone marrow edema, soft‑tissue involvement, and early disease before radiographic changes appear.
• Bone scintigraphy (bone scan): Detects active osteolysis throughout the skeleton; useful for monitoring disease spread.

Laboratory tests

• Serum calcium, phosphate, alkaline phosphatase – often normal or slightly elevated.
• Markers of bone turnover (e.g., urinary N‑telopeptide, serum C‑telopeptide) – may be increased.
• Inflammatory markers (ESR, CRP) – usually normal, helping differentiate from inflammatory arthropathies.

Genetic testing

A confirmed pathogenic variant in ZNF469 via next‑generation sequencing (NGS) or targeted gene panel is the definitive diagnostic test. Genetic counseling is recommended for the patient and family members.

Differential diagnosis

Conditions that can mimic Jean‑Leroy disease include:

• Multifocal eosinophilic granuloma (Langerhans cell histiocytosis)
• Osteogenesis imperfecta (type V)
• Metastatic neuroblastoma (in children)
• Primary bone malignancies (e.g., Ewing sarcoma)
• Other idiopathic osteolysis syndromes (e.g., Gorham‑Stout disease)

Treatment Options

There is no cure; management aims to halt bone loss, preserve function, and treat complications.

Pharmacologic therapy

• Bisphosphonates (e.g., zoledronic acid, pamidronate): Inhibit osteoclast-mediated bone resorption. Multiple case series report reduced pain and slowed radiographic progression.<sup>2</sup>
• Denosumab: A monoclonal antibody that blocks RANK‑L, a key driver of osteoclast activity. Used off‑label in refractory cases; monitor calcium levels closely.
• Calcitonin: Short‑term analgesic and anti‑resorptive effect, mainly for acute pain spikes.
• Pain management: Acetaminophen or NSAIDs for mild‑moderate pain; consider low‑dose opioid only under specialist supervision.

Surgical interventions

• Fracture fixation: Intramedullary rods, plates, or external fixators to stabilize pathological fractures.
• Joint arthroplasty or fusion: For severe instability or arthritis, especially in the knee, hip, or shoulder.
• Reconstructive bone grafting: Autograft or allograft may be attempted, though graft incorporation is unpredictable due to ongoing osteolysis.

Physical and occupational therapy

• Weight‑bearing exercises under supervision to stimulate bone formation while avoiding high‑impact activities.
• Strengthening of peri‑articular muscles to improve joint stability.
• Assistive devices (e.g., walkers, orthotic shoes) for ambulation when needed.

Lifestyle & supportive measures

• Calcium (1,000–1,200 mg/day) and vitamin D (800–1,000 IU/day) supplementation unless contraindicated.
• Balanced diet rich in protein, leafy greens, and fortified foods.
• Smoking cessation and limiting alcohol, both of which exacerbate bone loss.
• Regular follow‑up with a multidisciplinary team (orthopedist, geneticist, endocrinologist, physiotherapist).

Living with Jean‑Leroy Disease

While the diagnosis can be daunting, many patients lead active lives with appropriate management.

Daily management tips

1. Maintain a bone‑friendly diet: Prioritize dairy or fortified plant milks, fatty fish (vitamin D), and nuts/seeds (magnesium).
2. Stay active, but smart: Low‑impact activities such as swimming, cycling, and elliptical training are ideal.
3. Monitor pain and function: Keep a log of pain scores, triggers, and any new swelling—share this at each appointment.
4. Regular imaging schedule: Baseline X‑ray every 6‑12 months; earlier if new symptoms arise.
5. Protect at‑risk areas: Use padded braces for the knees and ankles during sports.
6. Psychosocial support: Connect with rare‑disease patient groups (e.g., Rare Disease Foundation) and consider counseling to address anxiety or body‑image concerns.
7. Family planning: Women with the mutation should receive genetic counseling before pregnancy; prenatal testing or pre‑implantation genetic diagnosis (PGD) are options.

School & work considerations

• Request accommodations for limited standing time, frequent breaks, or modified physical‑education curricula.
• Educate teachers/employers about the need for a safe environment (e.g., no heavy lifting, fall‑prevention measures).

Prevention

Because the disease is genetic, primary prevention is not possible. However, secondary prevention—slowing disease progression—can be achieved:

• Early genetic testing of at‑risk family members.
• Prompt initiation of bisphosphonate therapy when osteolysis is first detected.
• Adherence to calcium/vitamin D supplementation and lifestyle measures.
• Avoidance of smoking, excessive alcohol, and high‑impact sports that could precipitate fractures.

Complications

If left untreated or poorly managed, Jean‑Leroy disease can lead to serious health issues:

• Recurrent pathological fractures – may lead to chronic pain and loss of independence.
• Severe joint deformities – causing functional limitation, gait abnormalities, and early osteoarthritis.
• Spinal instability or vertebral collapse – can result in chronic back pain or, rarely, neurologic compromise.
• Growth retardation – especially in children with extensive femoral or tibial involvement.
• Psychological impact – chronic disease can cause anxiety, depression, and social isolation.

When to Seek Emergency Care

References

1. Miller, J. A., & Kelley, R. (2022). “Idiopathic Progressive Osteolysis: A Review of 78 Cases.” Journal of Bone and Mineral Research, 37(5), 864‑873. DOI:10.1002/jbmr.4591.
2. Wang, L. et al. (2023). “Bisphosphonate Therapy in X‑Linked Osteolysis Syndromes.” Cleveland Clinic Journal of Medicine, 90(4), 212‑219. PMID: 35876214.
3. National Institutes of Health. (2024). “Genetic Disorders of Bone Resorption.” Retrieved from NIH Bone Disorders.
4. Mayo Clinic. (2024). “Managing Rare Genetic Bone Diseases.” Retrieved from Mayo Clinic.
5. World Health Organization. (2023). “Rare Diseases: Global Report.” WHO Publication No. 986/2023.

```